{
    "clinical_study": {
        "@rank": "30154", 
        "arm_group": [
            {
                "arm_group_label": "Nalmefene 18 mg, then placebo", 
                "arm_group_type": "Experimental", 
                "description": "18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride"
            }, 
            {
                "arm_group_label": "Placebo, then Nalmefene 18 mg", 
                "arm_group_type": "Placebo Comparator", 
                "description": "18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride"
            }
        ], 
        "brief_summary": {
            "textblock": "To contribute to the understanding of the underlying neurobiological mechanism behind the\n      interaction of alcohol and nalmefene"
        }, 
        "brief_title": "Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge", 
        "condition": "Alcohol Dependence", 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject has alcohol dependence, diagnosed according to DSM-IV-TR\u2122.\n\n        Exclusion Criteria:\n\n          -  The subject is seeking treatment for alcohol dependence.\n\n          -  The subject has had <6 heavy drinking days (HDDs) in the 4 weeks prior to the\n             Screening Visit.\n\n          -  The subject has had an average alcohol consumption below high risk levels (that is,\n             60 grams of alcohol/day for men) <4 weeks prior to the Screening Visit.\n\n          -  The subject has >5 consecutive abstinence days in the 4 weeks prior to the Screening\n             Visit.\n\n          -  The subject has a Revised Clinical Institute Withdrawal Assessment of Alcohol Scale,\n             (CIWA-Ar), score \u226510.\n\n          -  The subject is, in the opinion of the investigator, at significant risk of suicide or\n             meets the exclusion criteria based on C-SSRS.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969617", 
            "org_study_id": "15660A", 
            "secondary_id": "2013-001154-98"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nalmefene 18 mg, then placebo", 
                "description": "One single oral dose Nalmefene on Day 1 and Placebo on Day 8", 
                "intervention_name": "Nalmefene 18 mg, then placebo", 
                "intervention_type": "Drug", 
                "other_name": "Selincro\u00ae"
            }, 
            {
                "arm_group_label": "Placebo, then Nalmefene 18 mg", 
                "description": "One single oral dose Placebo on Day 1 and Nalmefene on Day 8", 
                "intervention_name": "Placebo, then Nalmefene 18 mg", 
                "intervention_type": "Drug", 
                "other_name": "Selincro\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nalmefene"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }, 
                "name": "GB801"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Interventional, Randomized, Double-blind, Cross-over, Placebo-controlled Study to Investigate the Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Blood oxygen level dependent (BOLD) fMRI signal in the ventral striatum to reward responding using the monetary incentive delay task (MIDT) task", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969617"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of adverse events", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 8 and a 10-day safety follow up"
            }, 
            {
                "description": "Columbia-Suicide Severity Rating Scale (CSSRS) score", 
                "measure": "Risk of suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 8"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}